TY - JOUR
T1 - Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease
T2 - two-year follow-up of the SYNTAX II study
AU - Serruys, Patrick W
AU - Kogame, Norihiro
AU - Katagiri, Yuki
AU - Modolo, Rodrigo
AU - Buszman, Pawel E
AU - Íñiguez-Romo, Andrés
AU - Goicolea, Javier
AU - Hildick-Smith, David
AU - Ochala, Andrzej
AU - Dudek, Dariusz
AU - Piek, Jan J
AU - Wykrzykowska, Joanna J
AU - Escaned, Javier
AU - Banning, Adrian P
AU - Farooq, Vasim
AU - Onuma, Yoshinobu
PY - 2019/6/12
Y1 - 2019/6/12
N2 - AIMS: The purpose of the study was to investigate whether the favourable outcomes of state-of-the-art PCI in the SYNTAX II trial, demonstrated at one year, were maintained at two-year follow-up.METHODS AND RESULTS: The SYNTAX II study was a multicentre, single-arm study that investigated the impact of a contemporary PCI strategy on clinical outcomes in 454 patients with de novo three-vessel coronary artery disease, without left main disease. Clinical outcomes in SYNTAX II were compared to the predefined PCI (SYNTAX-I PCI) and coronary artery bypass graft (SYNTAX-I CABG) cohorts from the landmark SYNTAX trial (SYNTAX-I), selected on the basis of equipoise for long-term (four-year) mortality utilising the SYNTAX score II. At two years, major adverse cardiac and cerebrovascular events (MACCE: a composite of all-cause death, any stroke, myocardial infarction, or revascularisation) in SYNTAX II were significantly lower compared to SYNTAX-I PCI (13.2% vs. 21.9%, p=0.001). Furthermore, similar two-year outcomes for MACCE were evident between SYNTAX II PCI and SYNTAX-I CABG (13.2% vs. 15.1%, p=0.42).CONCLUSIONS: At two years, clinical outcomes with the SYNTAX II strategy remained superior to the predefined SYNTAX-I PCI cohort, and similar to the predefined SYNTAX-I CABG cohort.
AB - AIMS: The purpose of the study was to investigate whether the favourable outcomes of state-of-the-art PCI in the SYNTAX II trial, demonstrated at one year, were maintained at two-year follow-up.METHODS AND RESULTS: The SYNTAX II study was a multicentre, single-arm study that investigated the impact of a contemporary PCI strategy on clinical outcomes in 454 patients with de novo three-vessel coronary artery disease, without left main disease. Clinical outcomes in SYNTAX II were compared to the predefined PCI (SYNTAX-I PCI) and coronary artery bypass graft (SYNTAX-I CABG) cohorts from the landmark SYNTAX trial (SYNTAX-I), selected on the basis of equipoise for long-term (four-year) mortality utilising the SYNTAX score II. At two years, major adverse cardiac and cerebrovascular events (MACCE: a composite of all-cause death, any stroke, myocardial infarction, or revascularisation) in SYNTAX II were significantly lower compared to SYNTAX-I PCI (13.2% vs. 21.9%, p=0.001). Furthermore, similar two-year outcomes for MACCE were evident between SYNTAX II PCI and SYNTAX-I CABG (13.2% vs. 15.1%, p=0.42).CONCLUSIONS: At two years, clinical outcomes with the SYNTAX II strategy remained superior to the predefined SYNTAX-I PCI cohort, and similar to the predefined SYNTAX-I CABG cohort.
KW - Coronary Artery Bypass
KW - Coronary Artery Disease/surgery
KW - Follow-Up Studies
KW - Humans
KW - Percutaneous Coronary Intervention
KW - Treatment Outcome
U2 - https://doi.org/10.4244/EIJ-D-18-00980
DO - https://doi.org/10.4244/EIJ-D-18-00980
M3 - Article
C2 - 30636684
SN - 1774-024X
VL - 15
SP - e244-e252
JO - Eurointervention
JF - Eurointervention
IS - 3
ER -